New pill shows promise for Hard-to-Treat leukemia patients
NCT ID NCT04948333
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study tested an oral drug called asciminib in 199 adults with chronic myeloid leukemia (CML) whose cancer had not responded well to at least two previous treatments. The goal was to see how many patients achieved a major molecular response—a significant drop in leukemia-related genetic markers—after 48 weeks. Results help doctors understand how to best use this medication for people with limited options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
CABA, Buenos Aires, C1221ADC, Argentina
-
Novartis Investigative Site
Buenos Aires, C1114AAN, Argentina
-
Novartis Investigative Site
Graz, 8036, Austria
-
Novartis Investigative Site
Linz, 4010, Austria
-
Novartis Investigative Site
Vienna, 1140, Austria
-
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, 20211-030, Brazil
-
Novartis Investigative Site
São Paulo, 01227-200, Brazil
-
Novartis Investigative Site
Vancouver, British Columbia, V5Z 1M9, Canada
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Montpellier, 34295, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, 68305, Germany
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Kiel, 24116, Germany
-
Novartis Investigative Site
München, 80377, Germany
-
Novartis Investigative Site
Athens, 115 27, Greece
-
Novartis Investigative Site
Thessaloniki, 570 10, Greece
-
Novartis Investigative Site
Monza, MB, 20900, Italy
-
Novartis Investigative Site
Roma, RM, 00161, Italy
-
Novartis Investigative Site
Verona, VR, 37134, Italy
-
Novartis Investigative Site
George Town, Pulau Pinang, 10450, Malaysia
-
Novartis Investigative Site
Kota Kinabalu, Sabah, 88586, Malaysia
-
Novartis Investigative Site
Johor Bahru, 80100, Malaysia
-
Novartis Investigative Site
Kuala Selangor, 68000, Malaysia
-
Novartis Investigative Site
Khoudh, 123, Oman
-
Novartis Investigative Site
Katowice, 40-519, Poland
-
Novartis Investigative Site
Warsaw, 00-791, Poland
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Seoul, Korea, 03080, South Korea
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
Taegu, 41944, South Korea
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Bilbao, Bizkaia, 48013, Spain
-
Novartis Investigative Site
Santa Cruz, Santa Cruz De Tenerife, 38009, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Leeds, West Yorkshire, LS9 7TF, United Kingdom
-
Novartis Investigative Site
Cambridge, CB2 0QQ, United Kingdom
-
Novartis Investigative Site
London, SE1 9RT, United Kingdom
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
-
Novartis Investigative Site
Hanoi, 100000, Vietnam
-
Novartis Investigative Site
Ho Chi Minh City, 70000, Vietnam
Conditions
Explore the condition pages connected to this study.